RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000171.xml
Dtsch Med Wochenschr 2011; 136(40): 2045-2049
DOI: 10.1055/s-0031-1286392
DOI: 10.1055/s-0031-1286392
Prävention & Versorgungsforschung | Review article
Versorgungsforschung, Hypertensiologie© Georg Thieme Verlag KG Stuttgart · New York
Prävention des Schlaganfalls durch Blutdrucksenkung
Prevention of stroke by blood pressure loweringWeitere Informationen
Publikationsverlauf
eingereicht: 28.7.2011
akzeptiert: 21.9.2011
Publikationsdatum:
28. September 2011 (online)

Schlüsselwörter
Hypertonie - Schlaganfall - antihypertensive Therapie - Prävention - Blutdruckvariabilität - Zielblutdruck
Keywords
hypertension - stroke - antihypertensive therapy - prevention - blood pressure variability - target blood pressure
Literatur
- 1
Beckett N S, Peters R, Fletscher A E. et al .
Treatment of hypertension
in patients 80 years of age or older.
N Engl J Med.
2008;
358
1887-1898
MissingFormLabel
- 2
Cushman W C, Evans G W. et al .
ACCORD
Study Group: Effects of intensive blodd-pressure control in type
2 diabetes mellitus.
N Engl J Med.
2010;
362
1575-1595
MissingFormLabel
- 3
Dahlöf B, Sever P S, Poulter N R. et al .
Prevention of cardiovaskular events
with an an antihypertensive regimen of amlodipine adding perindopril
as required versus atenolol adding bendroflumethiazide as required,
in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure
Lowering Arm (ASCOT-BPLA):a multicentre randomised controlled trial.
Lancet.
2005;
366
895-906
MissingFormLabel
- 4 Deutsche Hochdruckliga e. V.
DHL® – Deutsche Hypertonie Gesellschaft: Leitlinien
zur Therapie der arteriellen Hypertonie. Heidelberg; 2008
MissingFormLabel
- 5
Elliot W J, Meyer P M.
Incident diabetes
in clinical trials of antihypertensive drugs: a network meta-analysis.
Lancet.
2007;
369
201-207
MissingFormLabel
- 6
Eriksson S E, Olsson J E.
Survival and
recurrent strokes in patients with different subtypes of stroke:
a fourteen-year follow-up study.
Cerebrovasc Dis.
2001;
12
171-180
MissingFormLabel
- 7
Giles M F, Rothwell P M.
Risk of stroke
early after transient ischaemic attack: a systematic review and
meta-analysis.
Lancet Neurol.
2007;
6
1063-1072
MissingFormLabel
- 8
Lindholm L H, Carlberg B, Samuelssson O.
Should beta blockers remain first choice in the treatment of
primary hypertension? A meta-analysis.
Lancet.
2005;
366
1545-1553
MissingFormLabel
- 9
Lüders S.
Drug therapy for the secondary prevention of stroke in hypertensive
patients. Current issues and options.
Drugs.
2007;
67
955-963
MissingFormLabel
- 10
MacMahon S, Rodgers A.
Primary and secondary
prevention of stroke.
Clin Exp Hypertens.
1996;
18
537-546
MissingFormLabel
- 11
Messerli F H, Mancia G, Conti C R. et al .
Dogma disputed: can aggressively lowering
blood pressure in hypertensive patients coronary artery disease
be dangerous?.
Ann Intern Med.
2006;
144
884-893
MissingFormLabel
- 12
Messerli F H, Bangalore S, Ruschitzka F.
Angiotensin receptor blockers: baseline therapy in hypertension?.
Eur Heart J.
2009;
30
2427-2430
MissingFormLabel
- 13
O’Donell M J, Xavier D, Liu L. et al .
Risk factors for ischemic and intracerebral
haemorrhagic stroke in 22 Countries (the INTERSTROKE study): a case-control
study.
Lancet.
2010;
376
112-123
MissingFormLabel
- 14
Progress Collaborative Group .
Randomised trial of a perindopril-based blood-pressure lowering
regimen among 6105 individuals with previous stroke or transient
ischaemic attack.
Lancet.
2001;
358
1033-1041
MissingFormLabel
- 15
Psaty B M, Lumley T, Furberg C D. et al .
Health outcomes associated with various
antihypertensive therapies used first line agents: a network meta-analysis.
JAMA.
2003;
289
2534-2544
MissingFormLabel
- 16
Rashid P, Leonardi-Bee J, Bath P.
Blood pressure reduction and secondary prevention of stroke
and other vascular events.
Stroke.
2003;
34
2741-2749
MissingFormLabel
- 17
Rothwell P M, Howard S C, Dolan E. et al .
Prognostic significance of visit-to-visit
variability, maximun systolic blood pressure, and episodic hypertension.
Lancet.
2010;
375
895-905
MissingFormLabel
- 18
Schrader J, Lüders S, Kulschewski A. et al .
Morbidity and mortality after stroke, eprosartan
compared with nitrendipine for secondary prevention: principal results
of a prospective randomized controlled study (MOSES).
Stroke.
2005;
36
1218-1226
MissingFormLabel
- 19
Schrader J.
Blutdrucksenkung nach Schlaganfall.
Dtsch Med Wochenschr.
2006;
131
758-761
MissingFormLabel
- 20
Skoog I, Lernfelt B, Landahl S. et al .
15-year longitudinal study of blood pressure
and dementia.
Lancet.
1996;
347
1141-1145
MissingFormLabel
- 21
Tu J V.
Reducing the global burden of stroke.
Lancet.
2010;
376
74-75
MissingFormLabel
- 22
Webb A J, Fischer U, Mehta Z, Rothwell P M.
Effects of
antihypertensive-drug class on interindividual variation in blood
pressure and risk of stroke: a systematic review and meta-analysis.
Lancet.
2010;
375
906-915
MissingFormLabel
- 23
Williams B, Lacy P S, Thom S M. et al .
Differential impact of blodd
pressure-lowering drugs on central aortic pressure and clinical
outcomes: principal results of the Conduit Artery Function Evaluation (CAFE)
study.
Circulation.
2006;
113
1213-1225
MissingFormLabel
- 24
Yusuf S, Diener H C, Sacco R L. et al .
Telmisartan to prevent recurrent stroke
and cardiovascular events.
N Engl J Med.
2008;
359
1225-1237
MissingFormLabel
- 25
Yusuf S, Hawken S, Ôunpuu S. et al on behalf of the INTERHEART study investigatorsE .
ffect of potentially modifiable risk factors associated with
myocardial infarction in 52 countries (the INTERHEARTstudy): case-control
study.
Lancet.
2004;
364
937-952
MissingFormLabel
Prof. Dr. Joachim Schrader
St. Josefs-Hospital
Krankenhausstr. 13
49661 Cloppenburg
Telefon: 04471/16-2951
Fax: 04471/16-2970
eMail: j.schrader@kh-clp.de